Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited
2022年 6月 27日
Read MoreZai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China
2022年 6月 10日
Read MoreZai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer
2022年 6月 03日
Read MoreZai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference
2022年 5月 31日
Read MoreZai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
2022年 5月 05日
Read More